November 2, 2018 07:52 AM EDT
Pharma

Il­lu­mi­na forks out $1.2B to buy ri­val Pa­cif­ic Bio­sciences, plac­ing long and short-read DNA tech un­der the same roof

ENDPOINTS

Il­lu­mi­na $ILMN is con­sol­i­dat­ing its pole po­si­tion in the gene se­quenc­ing mar­ket by ac­quir­ing small­er ri­val Pa­cif­ic Bio­sciences $PACB in a $1.2 bil­lion

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times